文献速递眼底病与葡萄膜炎

渗出性年龄相关性黄斑变性患者接受玻璃体腔抗血管内皮生长因子注射治疗的十年随访

TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS.
PubMed 文献 · Retina · 2020-01-01

这项回顾性队列研究纳入130只眼(115例患者),接受至少2次玻璃体腔抗血管内皮生长因子注射且随访至少10年,平均随访11.1±0.7年。每年至少接受一次注射的40只眼视力保持稳定(0.47±0.4 vs 0.58±0.5,P=0.28),而未每年注射的眼视力显著下降(0.67±0.5 vs 1.01±0.7,P<0.0001)。结论认为每年接受注射的眼在10年间视力稳定。

要点

  • 每年至少接受一次注射的眼10年间视力无显著变化(P=0.28)。
  • 未每年接受注射的眼视力显著下降(P<0.0001)。
  • 全部眼平均随访11.1±0.7年,平均注射45.1±32.3次。

核心结论

  • 接受玻璃体腔注射的渗出性年龄相关性黄斑变性眼中,每年至少注射一次的眼在10年间视力稳定。
  • 持续玻璃体腔抗血管内皮生长因子治疗可能使视力稳定10年甚至更久。

研究设计与样本

  • 回顾性队列研究,纳入接受至少2次玻璃体腔抗血管内皮生长因子注射且治疗后随访至少10年的渗出性年龄相关性黄斑变性眼。
  • 共130只眼(115例患者),平均随访11.1±0.7年,采用Snellen视力及光学相干断层扫描数据。
  • 亚组分析比较继续接受改良治疗延长方案抗血管内皮生长因子治疗者与停药超过1年者。

主要发现

  • 全部眼平均接受玻璃体腔注射45.1±32.3次,平均每年5至7次。
  • 基线平均logMAR视力0.61±0.5(Snellen视力20/81),最终平均logMAR视力0.88±0.7(20/152,P<0.0001)。
  • 每年至少接受一次注射的40只眼,基线与最终视力分别为0.47±0.4(20/59)与0.58±0.5(20/76),无显著变化(P=0.28)。
  • 未每年接受注射的眼,基线与最终视力分别为0.67±0.5(20/94)与1.01±0.7(20/205),显著下降(P<0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify the visual acuity outcomes of patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections over a 10-year period. METHODS: This was a retrospective, cohort study of eyes with exudative age-related macular degeneration that received ≥2 intravitreal anti-vascular endothelial growth factor injections and had at least 10 years of follow-up after the initiation of treatment. Snellen visual acuity was recorded at baseline and then annually until the last year of follow-up. Optical coherence tomography data were collected at the time of treatment initiation and at the last examination visit. A subanalysis was performed on patients who continued to receive anti-vascular endothelial growth factor therapy using a modified treat and extend protocol versus those who discontinued treatment for longer than 1 year. RESULTS: One hundred thirty eyes of 115 patients met the inclusion criteria. The mean follow-up after treatment initiation was 11.1 ± 0.7 years. Eyes received an average of 45.1 ± 32.3 intravitreal injections in total and a mean of 5 to 7 injections per year. The baseline mean logMAR visual acuity was 0.61 ± 0.5 (Snellen acuity 20/81), and the final mean logMAR visual acuity was 0.88 ± 0.7 (20/152, P value = <0.0001). There were 40 eyes that received at least one injection every year. These eyes did not have a significant change in visual acuity between the baseline and final examinations 0.47 ± 0.4 (20/59 vs. 0.58 ± 0.5 [20/76, P = 0.28]), whereas the eyes that did not receive at least one injection every year saw a significant decline in visual acuity 0.67 ± 0.5 (20/94 vs. 1.01 ± 0.7 [20/205, P < 0.0001]). CONCLUSION: Eyes with exudative age-related macular degeneration that received intravitreal injections every year had stable visual acuity over a 10-year period. Continuous intravitreal anti-vascular endothelial growth factor therapy may stabilize visual acuity for 10 years and potentially longer.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Starr MR, Kung FF, Mejia CA, et al. TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS. Retina. 2020. PMID: 31725524. doi:10.1097/IAE.0000000000002668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。